Athera Biotechnologies Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Out of Business

  • Employees
  • 4


  • Latest Deal Type
  • Out of Business

Athera Biotechnologies General Information


Operator of a biopharmaceutical company intended to address the unmet needs for anti-inflammatory therapeutics in the treatment of cardiovascular disease (CVD). The company's technology aims to develop targeted anti-inflammatory biological candidate drugs for the prevention and treatment of immunovascular diseases, enabling patients to reduce the risk of complications in vascular disease.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Corporate Office
  • Olof Palmes gata 29
  • 4th Floor
  • 111 22 Stockholm
  • Sweden

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Athera Biotechnologies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Out of Business 01-Nov-2022 0000 Completed Out of Business
5. Later Stage VC 21-Apr-2019 00.000 0000 Completed Clinical Trials - Phase 2
4. Later Stage VC 29-Aug-2017 00.000 00.000 Completed Clinical Trials - Phase 1
3. Secondary Transaction - Private 03-Dec-2015 00.000 00.000 Completed Clinical Trials - Phase 1
2. Grant 17-Jun-2013 $7.85M Completed Clinical Trials - Phase 1
1. Buyout/LBO Completed Startup
To view Athera Biotechnologies’s complete valuation and funding history, request access »

Athera Biotechnologies Patents

Athera Biotechnologies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202101962-D0 Methods and compositions Inactive 12-Feb-2021
GB-202000351-D0 Methods and compositions Inactive 10-Jan-2020
ES-2732838-T3 New antibodies against phosphorylcholine Active 09-Aug-2011 000000000
US-9803028-B2 Antibodies against phosphorylcholine Active 09-Aug-2011 000000000 00
US-20210238311-A1 Antibodies against phosphorylcholine Inactive 09-Aug-2011 C07K16/44
To view Athera Biotechnologies’s complete patent history, request access »

Athera Biotechnologies Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »